Trevi OCEAN-2 trial opens, cash runway extended
Trevi Therapeutics initiated Phase 3 OCEAN-2 for IPF-related cough and received positive FDA alignment on non-ILD programs, though it remains a clinical-stage biopharmaceutical with significant investor risk.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed